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Abstract
Background: NKX2–1, a key molecule in lung development, is highly expressed in non-small cell lung cancer
(NSCLC), particularly in lung adenocarcinoma (ADK), where it is a diagnostic marker. Studies of the prognostic role
of NKX2–1 in NSCLC have reported contradictory findings. Two microRNAs (miRNAs) have been associated with
NKX2–1: miR-365, which targets NKX2–1; and miR-33a, which is downstream of NKX2–1. We have examined the
effect of NKX2–1, miR-365 and miR-33a on survival in a cohort of early-stage NSCLC patients and in sub-groups of
patients classified according to the mutational status of TP53, KRAS, and EGFR.
Methods: mRNA and miRNA expression was determined using TaqMan assays in 110 early-stage NSCLC patients.
TP53, KRAS, and EGFR mutations were assessed by Sanger sequencing.
Results: NKX2–1 expression was upregulated in never-smokers (P = 0.017), ADK (P < 0.0001) and patients with
wild-type TP53 (P = 0.001). A negative correlation between NKX2–1 and miR-365 expression was found (ρ = −0.287;
P = 0.003) but there was no correlation between NKX2–1 and miR-33a expression. Overall survival (OS) was longer
in patients with high expression of NKX2–1 than in those with low expression (80.8 vs 61.2 months (P = 0.035),
while a trend towards longer OS was observed in patients with low miR-365 levels (P = 0.07). The impact of NKX2–1
on OS and DFS was higher in patients with neither TP53 nor KRAS mutations. Higher expression of NKX2–1 was
related to higher OS (77.6 vs 54 months; P = 0.017) and DFS (74.6 vs 57.7 months; P = 0.006) compared to low
expression. The association between NKX2–1 and OS and DFS was strengthened when the analysis was limited to
patients with stage I disease (P = 0.005 and P=0.003 respectively).
Conclusions: NKX2–1 expression impacts prognosis in early-stage NSCLC patients, particularly in those with neither
TP53 nor KRAS mutations.
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Background
Lung cancer is the leading cause of cancer-related death
in developed countries [1, 2]. In Europe 410,000 new
cases of lung cancer and 353,000 related deaths were es-
timated to occur in 2012 [3]. In the most frequent type,
non-small-cell lung cancer (NSCLC), more than 70% of
patients debut with locally advanced or metastatic dis-
ease [4]. In patients that present with early-stage disease,
surgery alone or surgery followed by cisplatin-based ad-
juvant treatment is the first line of treatment. Although
surgery is considered a curative treatment, 30–55% of
patients will relapse during the first two years [5]. These
data highlight the need to further investigate this disease
and consolidate useful prognostic markers.
NK2 homeobox 1 (NKX2–1), also known as thyroid
transcription factor-1 (TTF-1), is a key transcription fac-
tor that orchestrates the development of the lung, thy-
roid and forebrain in the embryonic period [6]. In adult
lung tissue, NKX2–1 is expressed in conducting airways
type II alveolar epithelial cells and in Clara cells and uni-
formly in the terminal respiratory unit [7]. NKX2–1 reg-
ulates surfactant protein transcription by directly
binding to the promoter of SP-A [8], SP-B [9], SP-C
[10], clara cell secretory protein (CCSP) [11], and T1〈
[12]. NKX2–1 is commonly used in clinical practice for
the differential diagnosis of the adenocarcinoma (ADK)
subtype of NSCLC [13, 14]. More than 70% of ADK are
positive for NKX2–1 by immunohistochemistry, inde-
pendent of disease stage [15].
Most of the studies that have examined the role of
NKX2–1 in oncogenesis have highlighted its role as
tumor suppressor. NKX2–1 inhibits proliferation by
inhibiting the embryonal proto-oncogene High Mobility
Group At-Hook 2 (HMGA2) [16]. In addition, NKX2–1
inhibits cell motility and metastatic capacity through
modification of intercellular junctions and cytoskeleton
elements. It promotes the expression of E-Cadherin,
Ocludin (OCLN) and CLN 1/18 [17]. It also inhibits
epithelial-to-mesenchymal transition (EMT) by repres-
sing transforming growth factor β (TGF β), which pro-
duces an increase of E-Cadherin levels [18]. NKX2–1
also activates MYBPH synthesis, which inhibits acto-
myosin filaments, crucial elements in cell migration [19].
In addition, NKX2–1 regulates transcription of P53, a
gene frequently lost or mutated in NSCLC patients [20,
21]. Reduced expression of NKX2–1 has been associated
with initiation and progression of invasive mucinous
lung ADK in patients harboring KRAS mutations [22].
MicroRNAs (miRNAs) are small non-coding RNAs
(22–24 nucleotides in length) that regulate post-
transcriptional processes via sequence-specific interac-
tions with the 3′ untranslated regions (UTR) of mRNA
[23]. Two miRNAs have been associated with NKX2–1:
miR-365 and miR-33a. Using an in silico method, Mu et
al. identified and validated miR-365 as a miRNA that
directly regulates NKX2–1 by binding to its 3’UTR and
inhibiting its translation [24]. Interestingly, a feed-back
signaling loop between miR-365 and TGF β was de-
scribed, illustrating that miR-365 participates in the
NKX2–1 repression of TGF β [24]. miR-33a, located
downstream of NKX2–1, was previously shown to have
cholesterol homeostasis regulatory activity and to bind
to the 3’UTR of HMGA2. These data indicate that
NKX2–1 upregulates miR-33a, which represses HMGA2
[25] and could inhibit EMT, thus controlling lung cancer
metastasis [26].
The prognostic value of NKX2–1 expression is contro-
versial. Although most studies report that lower expres-
sion of NKX2–1 is associated with shorter overall
survival (OS) in NSCLC [27–30], others report an
inverse prognostic correlation [31]. We hypothesized
that miR-365a, NKX2–1 and miR-33a could work to-
gether to influence growth and differentiation of lung
cancer cells and that the study of this axis could thus
help to understand the discrepancies observed in the
prognostic impact of NKX2–1. We have studied the
expression of NKX2–1 and its associated miRNAs,
miR-365 and miR-33a, in a cohort of 110 early-stage
NSCLC patients and correlated our findings with
overall survival (OS).
Methods
Patient samples
From June 2007 to November 2013, tumor tissue samples
were prospectively collected from 110 adult patients diag-
nosed with stage I-II NSCLC who underwent complete
surgical resection in our institution. All patients had Span-
ish ethnicity. Tissue samples were immediately immersed
in RNALater® (Ambion) and stored at −80 °C until pro-
cessing. Clinical data were recorded on admission: age,
gender, smoking history, preoperative pulmonary function
tests, chronic obstructive pulmonary disease (COPD),
Eastern Cooperative Oncology Group (ECOG) perform-
ance status (PS), clinical and postoperative staging accord-
ing to TNM 7th edition [32], type of surgical resection
and pathological findings (histological subtype, and the
presence of emphysema). Information regarding adjuvant
treatment, relapse and clinical outcomes was also re-
corded. The mutational status of TP53 and K-RAS was
assessed in all patients, and EGFR mutational status was
assessed in ADK patients.
RNA extraction and gene expression analysis
Total RNA was isolated from frozen tissue using TriZol®
Reagent (Life Technologies) according to the
manufacturer’s protocol. RNA from samples was quanti-
fied using a NanoDrop ND-1000 Spectrophotometer
(Fisher Scientific, Madrid, Spain).
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cDNA was obtained from 500 ng of total RNA using
the High Capacity cDNA Reverse Transcription Kit®
(Life Technologies) as per manufacturer’s protocol.
NKX2–1 mRNA expression levels were quantified using
a TaqMan Gene Expression assay (Hs00968940_m1) in a
7500 Real-Time PCR System (Life Technologies). Rela-
tive expression levels were calculated by 2-ΔΔCt method
using 18S as endogenous control.
miRNA quantification
miR-365 and miR-33a expression was analyzed using
TaqMan MicroRNA Assay (Applied Biosystems) as
previously described [33]. Relative quantification was
calculated using 2-ΔΔCt. Normalization was performed
with miR-191 [34]. All experiments were performed
in triplicate.
TP53, K-RAS and EGFR mutation analysis
PCR to identify TP53, K-RAS and EGFR mutations was
performed on 50-ng DNA samples and the Sanger se-
quencing process was performed by STAB Vida (Capar-
ica, Portugal). The mutation analysis for TP53 included
the exons 5–8 and used the following primers: exon 5
forward(F) 5′- GTTTCTTTGCTGCCGTCTTC-3′, 5 re-
verse (R) 5’-GAGCAATCAGTGAGGAATCAGA-3′;
exon 6F 5’-AGAGACGACAGGGCTGGTT-3′, 6R 5’-CT
TAACCCCTCCTCCCAGAG-3′; exon 7F 5’-TTGCCAC
AGGTCTCCCCAA-3′, 7R 5’-AGGGGTCAGAGGCAA
GCAGA-3′; exon 8F 5’-GGGACAGGTAGGACCTGA
TTT-3′, 8R 5’-TAACTGCACCCTTGGTCTCC-3′.
The mutation analysis for K-RAS included the codons
12 and 13 and used the following primers: F 5’-TTA
ACCTTATGTGTGACATGTTCTAA-3′, R 5’-AGAATG
GTCCTGCACCAGTAA-3′.
The mutation analysis for EGFR included the exons
18, 19, 20 and 21 and used the following primers: exon
18 F 5’-GCATGGTGAGGGCTGAGGT-3′, 18R 5’-TG
CAAGGACTCTGGGCTCC-3′; exon 19 F 5’-TGCAT
CGCTGGTAACATCCA-3′, 19R 5’-GAAAAGGTGGGC
CTGAGGTT-3′; exon 20F 5’-TCCTTCTGGCCACCA
TGC-3′, 20R 5’-TGGCTCCTTATCTCCCCTCC-3′;
exon 21F 5’-ATGCAGAGCTTCTTCCCATGA-3′, 21R
5’-CAGGAAAATGCTGGCTGACC-3′.
TTF-1 immunohistochemistry staining
IHC was performed on formalin-fixed, paraffin-
embedded tissue sections of 16 lung carcinomas and 3
normal lung controls from the Pathology Service of the
Hospital Clinic of Barcelona after review by a thoracic
pathologist. 4-μm-thick transverse sections of formalin-
fixed, paraffin-embedded tissue were serially cut and
mounted onto Dako Silanized Slides (S3003; Dako,
Glostrup, Denmark). For antigen retrieval, the sections
were manually immersed in Target Retrieval solution,
high pH (Dako) and heated in a water bath at 95–99uC
for 20 min. Endogenous peroxidase activity was quenched
by immersion in Dako Real Peroxidase-Blocking solution
for 10 min. The tissue sections were incubated with pri-
mary antibody against TTF1 (1:100, 8g7g3/1, DAKO, glos-
trop, Denmark). The slides were then washed in Tris–HCl
and detected with horseradish peroxidase-conjugated
anti-rabbit EnVision + kit (DAKO). Finally, sections were
stained with hematoxylin. All slides were blindly scored by
the same two pathologists. Nuclear staining of tumor cells
was considered TTF1+. Tumors with completely no TTF1
expression in nuclei were de ned as TTF1 − .
Statistical analyses
The primary endpoint of the study was OS, defined as the
time between surgery and death from any cause. Kaplan-
Meier curves for OS were drawn and compared by means of
a log-rank test. All factors with P ≤ 0.1 in the univariate ana-
lysis were included in the Cox multivariate regression ana-
lyses for OS. Optimal cut-offs of NKX2–1 expression data
for OS were assessed by means of maximally selected log-
rank statistics using the Maxstat package (R statistical pack-
age, v. 2.8.1, Vienna, Austria) [35] and confirmed by the
Kaplan-Meier test. Student T-Test or Mann-Whitney U test,
as appropriate, were used for comparisons between two
groups or ANOVA when more than two groups were com-
pared. Pearson correlation was used to compare the NKX2–
1 expression with its associated miRNAs. All statistical ana-
lyses were performed using PASW Statistics 21 (SPSS Inc.)
and R v2.8.1. The level of significance was set at P ≤ 0.05.
Results
Patients
The analysis included 110 patients. The mean age was
66 years (range 32–84) and 79.1% were male. All pa-
tients had ECOG PS 0 or 1. The majority were current
or former smokers. ADK was the most frequent histo-
logical subtype (51.8%) and SCC was the second most
frequent (40%). Other subtypes included large-cell car-
cinoma (4.5%), mixed adenosquamous carcinoma (1.8%),
and lepidic ADK (1.8%). The majority of patients had
stage I disease (73.6%). Twenty-six patients (23.6%) re-
ceived adjuvant chemotherapy, 19 for stage II and 7 for
stage I disease with T > 4 cm. The mean follow-up was
45 months (range, 7.6–97.7). K-RAS mutations were de-
tected in 19.1% of all patients and TP53 mutations in
30%. The distribution of TP53 mutations by exon was:
12 mutations in exon 5; six in exon 6; five in exon 7;
and ten in exon 8. EGFR mutations were detected in
24.1% of patients with ADK (Table 1).
NKX2–1, miR-365 and miR-33a expression
NKX2–1 was differentially expressed according to the
smoking status of the patient (ANOVA P = 0.03) and
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was upregulated in never-smokers compared to current
and former smokers (P = 0.025; Fig. 1a).
NKX2–1 expression was also significantly higher in
patients with ADK than in those with squamous cell
carcinoma (SCC) (P < 0.001; Fig. 1b). A random selection
of samples with ADK were assessed by IHC for
NKX2–1. NKX2–1 expression was higher in ADK
patients who were IHC-positive for NKX2–1(P = 0.043;
Additional file 1: Figure S1).
Patients harboring TP53 mutations had lower NKX2–1
levels than those with wild-type (WT) TP53 (P = 0.001;
Fig. 1c). ANOVA analysis showed that NKX2–1 was dif-
ferentially expressed in TP53-mutated patients according
to exon location (P = 0.02; Fig. 1d). No significant
differences in NKX2–1 expression were observed
according to KRAS or EGFR mutational status. miR-365
expression was significantly lower in ADK than in SCC
patients (P = 0.003; Fig. 1e).
When we assessed the potential correlation between the
expression of NKX2–1, miR-365, and miR-33a, expression,
we found only a negative correlation between NKX2–1 and
miR-365 expression (ρ = −0.287, P = 0.003; Fig. 1f).
The prognostic value of NKX2–1, miR-365 and miR-33a in
early-stage NSCLC
Using the optimal cutoff identified by Maxstat, patients
were classified as having high or low NKX2–1 expres-
sion. Mean OS in patients with high NKX2–1 expression
was 80.8 months (95% CI 69.6–92), compared to
61.2 months (95% confidence interval [CI] 51.3–71.1) in
those with low NKX2–1 expression (P = 0.035; Fig. 2a).
In addition, patients with high NKX2–1 expression had
longer DFS than those with low expression levels (71.7
vs 52.1 months; P = 0.073; Additional file 1: Figure S2A)
When the analysis was limited to patients with stage I
disease, mean OS was 79.7 months (95% CI 67.1–92.3)
in patients with high NKX2–1 expression and
57.0 months (95% CI 45.2–68.9) in those with low
NKX2–1 expression (P = 0.031; Fig. 2b).
Patients with high levels of miR-365 showed a trend
toward shorter OS than those with high levels (entire co-
hort: 60.9 vs 79.2 moths, P = 0.073; Stage I disease: 58.3 vs
76.6 months, P = 0.118; Additional file 1: Figure S3). No
association between miR-33a and OS was observed.
The prognostic value of NKX2–1 according to TP53, KRAS
and EGFR mutational status
Since NKX2–1 has previously been linked to TP53 [20],
KRAS [22] and EGFR [36], we explored its prognostic
impact according to the mutational status of these genes
in our entire cohort. No significant differences in OS ac-
cording to NKX2–1 levels were found in patients with
TP53, KRAS or EGFR mutations. However, in patients
without TP53 mutations, OS for those with high
NKX2–1 expression was 80.36 months (95% CI 68.1–
92.6), compared to 56.4 months (95% CI 43.3–67.5) for
those with low NKX2–1 expression (P = 0.048; Add-
itional file 1: FigureS4A). In patients without KRAS
Table 1 Main patient characteristics
Characteristics Value N = 110 OS NKX2–1
N (%) p-value p-value
Sex Male 87 (79.1) 0.019 0.196
Female 23 (20.9)
Age, yrs Mean (Range) 66.1 (32–84) 0.018 0.181
<=65 51 (46.4)
>65 59 (53.6)
ECOG PS 0 20 (18.2) 0.067 0.109
1 90 (81.8)
Stage I 81 (73.6) 0.334 0.429
II 29 (26.4)
Histology ADK 57 (51.8) 0.325 p <
0.001
SCC 44 (40)
Large-cell
Carcinoma
5 (4.5)
Lepidic ADK 2 (1.8)
Mixed
adenosquamous
2 (1.8)
Type of surgery Lobectomy/
Bilobectomy
94 (85.5) 0.973 –
Pneumonectomy 5 (8.1)
Atypical Resection 7 (6.4)
Smoking history Current Smoker 40 (36.3) 0.075 0.025
Former Smoker 58 (52.7)
Never smoker 12 (10.9)
Adjuvant treatment Yes 26 (23.6) 0.663 –
No 84 (76.4)
Relapse No 76 (69.1) – 0.794
Yes 34 (30.9)
Emphysema Yes 54 (49.1) 0.223 0.389
No 49 (44.5)
Unknown 7 (6.4)
COPD Yes 71 (64.5) 0.574 0.127
No 39 (35.5)
DLCO (%) Mean (Range) 73 (35–100) – –
Molecular Features TP53 mutation 33/104 (30) 0.680 0.001
KRAS mutation 21/109
(19.1)
0.815 0.204
EGFRa 14/58 (24.1) 0.109 0.696
OS overall survival, ECOG PS Eastern Cooperative Oncology Group performance status,
ADK adenocarcinoma, SCC squamous cell carcinoma, COPD chronic obstructive
pulmonary disease, DLCO diffusing capacity of the lung for carbon monoxide
aEGFR mutational status was assessed only in adenocarcinoma patients
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Fig. 1 NKX2–1 and miR-365 expression. NKX2–1 expression according to a smoking status, b histology, c TP53 mutational status, and d exon location
of TP53 mutation. e miR-365 expression according to histology. f Pearson correlation graph of NKX2–1 and miR-365 expression
a b
Fig. 2 Kaplan Meier analysis of overall survival according to NKX2–1 expression levels in a the entire cohort and b patients with stage I disease
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mutations, high NKX2–1 expression was also associated
with longer OS. OS for those with high NKX2–1 expres-
sion was 79.9 months (95% CI 68.7–91.1), compared to
60.2 months (95% CI 49.3–71.1) for those with low
NKX2–1 expression (P = 0.027; Additional file 1: Figure
S4B). These associations were maintained when the ana-
lysis was limited to stage I patients (TP53, P = 0.019;
KRAS: P = 0.020; Additional file 1: FigureS5A–D). In
patients without EGFR mutations, there was no associ-
ation between NKX2–1 expression and OS.
Among patients with neither TP53 nor KRAS muta-
tions, the prognostic impact of NKX2–1 expression
was even greater. OS was 77.6 months (95% CI 66.4–
88.7) for patients with high NKX2–1 expression and
54 months (95% CI 42.1–65.9) for those with low ex-
pression (P = 0.017; Fig. 3a). DFS was 74.6 months
(95% CI 61.5–87.8) for patients with high NKX2–1
expression and 45.35 months (95% CI 22–57.7) for
those with low expression (P = 0.006; Additional file
1: FigureS2B). This association was maintained when
the analysis was limited to stage I patients in OS
(76.9 [95% CI 65.1–88.7] vs 46.1 [95% CI 32.3–59.8]
months, respectively; P = 0.005; Fig. 3b), and DFS
(73.5 [95% CI 59.5–87.6] vs 39.6 [95% CI 26–53.2]
months, respectively; P = 0.003).
In the multivariate analysis of all patients without
TP53 or KRAS mutations, including age, sex, disease
stage, adjuvant therapy, and NKX2–1 expression,
NKX2–1 expression emerged as an independent
prognostic factor for OS (OR 5.335, 95% CI 1.329–
21.421; P = 0.018), together with stage (P = 0.018) and
adjuvant therapy (P = 0.048).
In a multivariate analysis NKX2–1 emerges as the only
independent prognostic factor for DFS (OR 4.333, 95%
CI 1.466–12.807; P = 0.008).
Discussion
The potential prognostic impact of NKX2–1 in NSCLC
is unclear. Several studies have found an association be-
tween low NKX2–1 expression and good prognosis [27–
30, 37, 38] while others have reported an association
with poor prognosis [39, 40] and still others have found
no association at all [41–43]. In the present study, we
assessed NKX2–1 expression in a cohort of 110 patients
with stage I-II NSCLC who had undergone surgical re-
section as their first therapeutic approach. Our findings
indicate that high NKX2–1 expression is associated with
longer OS both in the entire cohort (P = 0.035) and in
the subgroup of stage I patients (P = 0.031). Moreover,
among patients with neither TP53 nor KRAS mutations,
NKX2–1 expression emerged as an independent prog-
nostic factor for OS (OR 5.335; P = 0.018) and DFS (OR
4.333, P = 0.008).
The conflicting findings of previous studies may be
due to several factors, including the techniques used for
NKX2–1 analysis and the heterogeneity of patient
cohorts.
Most of the studies evaluated NKX2–1 expression by
Immunohistochemistry [38], a technique that only differ-
entiates between the presence or absence of a protein
but cannot quantify the levels of expression, although in
some studies [30] the authors use an automated quanti-
tative analysis of protein concentration within subcellu-
lar compartments to establish a range of expression. We
have evaluated NKX2–1 levels using RT-PCR, which is a
highly sensitive technique that can better classify
patients with intermediate levels of a gene.
Arguably, the most important difference between stud-
ies of the prognostic impact of NKX2–1 lies in the
clinical characteristics of the patients included, especially
disease stage. A meta-analysis of 2235 patients included
a b
Fig. 3 Kaplan Meier analysis of overall survival according to NKX2–1 expression levels in patients harboring neither TP53 nor KRAS mutations in a
the entire cohort and b patients with stage I disease
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in 17 studies of NKX2–1 found that 937 patients (80%)
had stage IIIb-IV disease [38]. In fact, the few studies
reporting a negative prognostic impact for high NKX2–1
expression were performed in cohorts enriched in stage
IIIb patients. Since the inclusion of these patients with
locally advanced disease may well confound the identifi-
cation of prognostic markers, we focused our study on a
well-characterized cohort of early-stage patients. Our re-
sults are in line with other previous studies [27] where
high NKX2–1 expression was related to longer survival.
Interestingly, this association was maintained in the sub-
group of stage I NSCLC patients, who had not received
adjuvant treatment after surgery, suggesting a clear
prognostic role for NKX2–1 mRNA expression.
NKX2–1 expression was upregulated in our patients
with wild-type TP53. This can be explained by previ-
ous findings that NKX2–1 has been linked to regula-
tion of TP53 transcription via LKB1 loss and IKKβ/
NF-κB activation [20, 44].
. NKX2–1 gene amplification displayed a positive cor-
relation with the presence of KRAS mutations; however,
its prognostic impact remains controversial. In a Japa-
nese ADK cohort, NKX2–1 amplification was an inde-
pendent predictor of poor prognosis [45, 46] NKX2–1
has also been linked to KRAS in that NKX2–1 gene hap-
loinsufficiency in patients harboring KRAS mutations,
with a consequent loss of function of NKX2–1, may pro-
mote tumorigenesis in mucinous ADK [47]. In our pa-
tients, however, we found no significant differences in
NKX2–1 expression according to KRAS status. Never-
theless, when we analyzed the effect of NKX2–1 expres-
sion on OS in patient subgroups classified according to
TP53 and KRAS mutation status, we found a remarkable
impact among patients with both wild-type TP53 and
wild-type KRAS. OS in these patients was much longer
for patients with high NKX2–1 levels – both in the en-
tire cohort (P = 0.017) and in stage I patients (P = 0.005).
Furthermore, in an exploratory analysis in this
subgroup of patients, we found a strong association
between high NKX2–1 expression and longer disease-free
survival – again both in the entire cohort (P = 0.006) and
in patients with stage I disease (P = 0.003). These findings
suggest that NKX2–1 functions are linked to the nor-
mal functioning of TP53 and KRAS and that muta-
tions in these genes influence the prognostic impact
of NKX2–1 expression.
As expected, NKX2–1 expression in our cohort was
higher in ADK than in SCC patients, although high
NKX2–1 expression has previously been described in
SCC as well [48]. Moreover, we observed an inverse
correlation between smoking habit and NKX2–1
levels that is in line with previous reports [49, 50],
suggesting that NKX2–1 downregulation could be
related to smoking habits.
The underlying mechanism of NKX2–1 as a tumor
suppressor is not fully understood but we speculated
that it might be linked to its associated miRNAs, miR-
365 and miR-33a. We found a negative correlation be-
tween miR-365 and NKX2–1 expression, indicating that
miR-365 directly regulates NKX2–1. We also observed
an inverse relation between miR-365 and NKX2–1 ex-
pression in ADK vs SCC, where miR-365 expression was
lower in ADK patients while NKX2–1 expression was
higher. Moreover, patients with high levels of miR-365
showed a trend towards shorter OS (P = 0.073). Taken
together, these findings provide further evidence for a
regulatory role of miR-365 over NKX2–1. In contrast,
no significant correlation between NKX2–1 and miR-
33a was observed, suggesting that factors other than
NKX2–1 are involved in the regulation of miR-33a.
Conclusions
The present study confirms a prognostic role for NKX2–1
in early-stage resected NSCLC patients, particularly in
those harboring neither TP53 nor KRAS mutations.
NKX2–1 expression may thus prove useful for the risk
stratification of early-stage NSCLC patients and could be
considered when deciding on adjuvant therapy strategies.
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